Trending...
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
- Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI
- Colorado Scenthound Locations Partner with Humane Colorado to Give Adopted Dogs a "Clean Start"
LIVONIA, Mich.--(BUSINESS WIRE)--Hygieia, a digital therapeutics company for insulin therapy, has successfully licensed its d-Nav insulin management technology to Movement Group, a provider of health and wellness programs to integrated health delivery networks in Israel. The agreement is part of an accelerated strategy to expand its d-Nav insulin titration technology globally.
d-Nav is the first FDA-cleared technology to autonomously adjust insulin dose recommendations to correspond to a patient's changing insulin needs. Patients get the correct insulin dose at each injection, without the need for physician intervention. Studies have shown that nearly 90 percent of d-Nav patients have improved A1C levels within 90 days*, without increasing the risk for hypoglycemia**.
Movement currently offers a diabetes prevention program. The d-Nav license agreement enables Movement to add an insulin management program to its existing services. Movement is offering the program to patients within the largest integrated managed care and delivery networks in Israel.
More on Michimich.com
To assist in expanding the d-Nav Technology internationally, Hygieia has appointed technology entrepreneur Gilad Lederer as its new head of global business development. Lederer is the co-founder of OTM Technologies, Ltd., and an investor in and advisor to several technology and private equity companies.
"This agreement with Movement extends access to potentially lifesaving technology for patients in Israel with type 2 diabetes taking insulin," said Lederer. "This is an exciting chapter in Hygieia's international journey, and we are looking for additional partners worldwide to license the d-Nav Technology."
On the heels of the Movement agreement is the news that the National Health Service in Northern Ireland extended its d-Nav license. Northern Ireland's NHS was the first international licensee of the d-Nav Technology.
Many patients from Northern Ireland who have been on the d-Nav program for more than seven years continue to show excellent results with an average A1C at 7% throughout their time on the program.
Organizations and providers that license d-Nav Technology receive complete information and ongoing consultation on how to build the insulin management program around the d-Nav Technology. For more information, contact +1-734-743-2838.
About Hygieia/ d-Nav Insulin Management Program
Hygieia is the developer of d-Nav®, the first FDA-cleared technology to autonomously adjust insulin doses directly to the patient. d-Nav's AI-powered technology automatically interprets data and independently initiates insulin management. The d-Nav Insulin Management Program adds clinical support that helps people with type 2 diabetes adjust their insulin doses according to their body's changing insulin needs. Studies have shown that nearly 90 percent of people using d-Nav report lower A1C in just three months* without increasing the risk for hypoglycemia**. The d-Nav Insulin Management Program has been peer-reviewed with studies published in leading medical journals. Hygieia is headquartered in Livonia, Michigan. Learn more at d-Nav.com.
More on Michimich.com
* John E Schneider et al. Impact of a Novel Insulin Management Service on Non-insulin Pharmaceutical Expenses. J Health Econ Outcomes Res. 2018 Feb 20;6(1):53-62. https://jheor.org/article/9783
** Richard M Bergenstal et al. Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial. Lancet 2019 Mar 16;393(10176):1138-1148. https://pubmed.ncbi.nlm.nih.gov/30808512/
Contacts
Debbie Reinheimer, debbie@reinheimerpr.com
d-Nav is the first FDA-cleared technology to autonomously adjust insulin dose recommendations to correspond to a patient's changing insulin needs. Patients get the correct insulin dose at each injection, without the need for physician intervention. Studies have shown that nearly 90 percent of d-Nav patients have improved A1C levels within 90 days*, without increasing the risk for hypoglycemia**.
Movement currently offers a diabetes prevention program. The d-Nav license agreement enables Movement to add an insulin management program to its existing services. Movement is offering the program to patients within the largest integrated managed care and delivery networks in Israel.
More on Michimich.com
- $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
- $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
- Rocket Companies Completes Acquisition of Redfin
- Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
- Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
To assist in expanding the d-Nav Technology internationally, Hygieia has appointed technology entrepreneur Gilad Lederer as its new head of global business development. Lederer is the co-founder of OTM Technologies, Ltd., and an investor in and advisor to several technology and private equity companies.
"This agreement with Movement extends access to potentially lifesaving technology for patients in Israel with type 2 diabetes taking insulin," said Lederer. "This is an exciting chapter in Hygieia's international journey, and we are looking for additional partners worldwide to license the d-Nav Technology."
On the heels of the Movement agreement is the news that the National Health Service in Northern Ireland extended its d-Nav license. Northern Ireland's NHS was the first international licensee of the d-Nav Technology.
Many patients from Northern Ireland who have been on the d-Nav program for more than seven years continue to show excellent results with an average A1C at 7% throughout their time on the program.
Organizations and providers that license d-Nav Technology receive complete information and ongoing consultation on how to build the insulin management program around the d-Nav Technology. For more information, contact +1-734-743-2838.
About Hygieia/ d-Nav Insulin Management Program
Hygieia is the developer of d-Nav®, the first FDA-cleared technology to autonomously adjust insulin doses directly to the patient. d-Nav's AI-powered technology automatically interprets data and independently initiates insulin management. The d-Nav Insulin Management Program adds clinical support that helps people with type 2 diabetes adjust their insulin doses according to their body's changing insulin needs. Studies have shown that nearly 90 percent of people using d-Nav report lower A1C in just three months* without increasing the risk for hypoglycemia**. The d-Nav Insulin Management Program has been peer-reviewed with studies published in leading medical journals. Hygieia is headquartered in Livonia, Michigan. Learn more at d-Nav.com.
More on Michimich.com
- Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
- Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
- NEW CHILDREN'S BOOK RELEASE: "Mommy, Where Is My Daddy?" by Tracy L. Gray
- UNIVERSAL MUSIC GROUP AND THE UCLA HERB ALPERT SCHOOL OF MUSIC ESTABLISH THE BERRY GORDY MUSIC INDUSTRY SCHOLARSHIP TO HONOR THE LEGACY OF A MUSIC PIONEER
- AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
* John E Schneider et al. Impact of a Novel Insulin Management Service on Non-insulin Pharmaceutical Expenses. J Health Econ Outcomes Res. 2018 Feb 20;6(1):53-62. https://jheor.org/article/9783
** Richard M Bergenstal et al. Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial. Lancet 2019 Mar 16;393(10176):1138-1148. https://pubmed.ncbi.nlm.nih.gov/30808512/
Contacts
Debbie Reinheimer, debbie@reinheimerpr.com
Filed Under: Business
0 Comments
Latest on Michimich.com
- databahn Launches GenAI Sales Intelligence Platform to Revolutionize Fortune 500 and Global 2000 Account Research
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
- PrideStaff Detroit (West) Named One of Detroit's Top Staffing Agencies for Second Year by ThreeBestRated®
- Colorado Scenthound Locations Partner with Humane Colorado to Give Adopted Dogs a "Clean Start"
- Endoacustica Europe Unveils iPhone 13 Pro Max Spy Phone—Pure Hardware, Zero Software Changes
- Suzanne Harp named Managing Director in Texas, USA
- $10 Million Acquisition of GXR World Sports Assets Energizes Global Launch of Sports.com Super App by Online Lottery-Sports Game Provider: Lottery.com
- Shop American Made Goods: New Online Marketplace My American Goods Curates the Best of U.S. Made
- Investor Spotlight: Cycurion, Inc. (N A S D A Q: CYCU) Secures $69M in Contracts Amid Surging Demand for AI-Powered Cybersecurity Solutions
- $328 Million Global Stroke Rehab Market Opportunity Awaits AI Telehealth Leader Following Selection for NIH Funded Phase 3 Clinical Study: VSee Health
- Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI
- VoodooSoft Unveils SiriusLLM: The World's First ChatGPT-Like AI Malware Detection Engine
- This Ain't Press. This Is Pressure — Star Command by RansomXX is Out Now
- The AI CEO™ Launches Next-Gen Sales Assistant for Equipment Finance Professionals
- PGA Tour's Rocket Mortgage Classic: Detroit Readies for a Championship Clash
- An Exclusive VIP Reception Honoring Vocal Prodigy Alliana Lili Yang's Remarkable Achievements and Magazine Cover Spotlight
- Joyce Carol Oates Returns to Hard Case Crime With DOUBLE TROUBLE
- New AI Academy Helps Therapists Embrace Tech Without Losing Their Humanity
- IQSTEL Surges Toward $400M Run Rate with $101.5M in Revenue—Reinforces Billion-Dollar Vision Backed by Fintech, AI, and Cybersecurity
- Alpha Modus Files 7th IP Action Against Rackspace Following $3M CEO Investment and Strategic Partnership Expansion